allergies, and most have ocular involvement 3 . Seasonal allergic conjunctivitis (SAC) affects 15% of the UK population 4 , in spring when the predominant airborne allergen is tree pollen and in summer when the predominant allergen is grass pollen; or in fall when the predominant allergen is weed pollen 5 .
Allergic conjunctivitis is an immuno-pathological disease. It is a typical Type-1 hypersensitivity reaction mediated by IgE 6 . Conjunctival mast cell degranulation plays a major role in ocular allergic disease and so treatment option should be concentrated on preventing this process or of antagonizing the effects of the primary mediator, histamine 7 .
Topical antihistaminic agents not only provide faster and better relief than systemic antihistamines, but they may also possess a longer duration of action than other classes like pure mast cell stabilizers, NSAIDs and corticosteroids. Some topical multiple-action H1 receptor antagonists (olopatadine, ketotifen, azelastine and epinastine) have been shown to prevent activation of inflammatory cell and inhibit release of inflammatory mediators 8 . Olopatadine is a new selective H1 antagonist that has mast cell stabilizing properties and has been shown to affect release of mediators from conjunctival epithelial cells 9 .
H1 selectivity of olopatadine is superior to that of other ocular antihistamines 10 . Olopatadine hydrochloride 0.1% has a rapid onset of action and has strong, selective antihistaminic and mast cell stabilizing action. It is very well tolerated when instillated providing patients with rapid, effective and long lasting relief from the signs and symptoms of allergic conjunctivitis 6 Now a day's treatment for allergic conjunctivitis has markedly expanded, providing more opportunities to choose a therapy but often leaving physicians confused over the variety of options. Information is limited about clinical outcome of patients with Allergic Conjunctivitis in our prospect. Lot of works have been done with olopatadine abroad, but so far we know there was no study done in our country regarding the effect of recently available drugs olopatadine on eye.
With this background, we designed to carry out this study to
Abstract:
A Patients appeared with the signs and symptoms of Allergic Conjunctivitis e.g.ocular itching, hyperaemia, dry eye, tearing, photophobia, pain eye, headache, mucus discharge, lid oedema etc. We studied on the patient with hyperaemia, tearing, ocular itching and photophobia in this single centre study as these signs & symptoms were included in the previous studies 6, 11 .
Every patient were given olopatadine hydrocloride 0.1%, one drop in the each eye every 12 hrs. Scoring (Table-I) of hyperaemia, itching, tearing, and photophobia were recorded just before and after 2 weeks of drug therapy. During drug therapy the patients were instructed to report to Ophthalmology OPD (out patient department) or to contact with the chief investigator if any problem aroused; such as, foreign body sensation/stinging, headache, sedation, dry eye, worsening of symptoms/non response to therapy etc. Each patient was evaluated 30 min and 2 weeks after treatment initiation for side effect ( Table-II) .
find out efficacy and safety of olopatadine hydrocloride in the treatment of allergic conjunctivitis.
Materials and methods
A prospective interventional study was carried out in the Department of Ophthalmology of Sylhet MAG Osmani Medical College Hospital. The patients who attended the ophthalmology out patient department of Sylhet MAG Osmani Medical College Hospital (SOMCH) with the diagnosis of acute allergic conjunctivitis were taken as the study subjects, as per inclusion criteria-a allergic conjunctivitis patient with hyperaemia, tearing, ocular itching and photophobia and exclusion criteria-associated with other systemic or ocular illness (bronchial asthma), eczema, dry eye, uveitis, infective conjunctivitis, receiving systemic or topical ocular medication, pregnancy etc as described by Aguilar 2000 6 ; Yaylali 11 . After fulfilling the selection criteria, patients who were found to be eligible to include in the study, were selected randomly as every patient with even registered number received Olopatadine Permission of the study was taken from the ethical committee of Sylhet MAG Osmani Medical College. Informed written consent was taken from the patients.
OBSERVATION AND RESULTS
The study was conducted on 40 patient with age range 12 to 50 yrs. mean age 28.33± 10.9 years and male female ratio was 9:11.
Effect of Olopatadine Hydrochloride on sign and symptoms of Allergic Conjunctivitis:
Before administration of Olopatadine hydrochloride hyperaemia score was recorded as 1.90 ± 0.304, while after 2 weeks it was recorded as 0.08 ± 0.267. The difference in hyperaemia score with administration of Olopatadine was statistically significant (p<0.001) and Olopatadine decreased hyperaemia by 95.78%. [ Table-III] Tearing score, before administration of Olopatadine was 1.13 ± 0.607. After 2 weeks, tearing score was 0.03 ± 0.158. Olopatadine decreased tearing score significantly after 2 weeks (p<0.001) and here reduction was 97.34%. [ Table-III] Itching score, before administration of Olopatadine was 2.45 ± 0.677, 2 weeks after administration score was recorded as 0.30 ± 0.608. These differences in itching scores before and after administration of Olopatadine was statistically significant (p<0.001). The decline in itching scores was 87.75%. [ Table-III] 2 weeks after administration of Olopatadine, photophobia was recorded 0.05 ± 0.221, while before initiation of treatment it was 1.27 ± 0.452. This changes between photophobia scores before and after administration of Olopatadine was statistically significant (p<0.001) and here the reduction in percentage scores of photophobia was 96.06%. [ Table- comfortable; which they found more efficacious in reducing symptoms of allergy. In our study, we scored s/s before treatment and after 2 weeks and our study result also showed that olopatadine is significantly effective and safe.
Behar and Kostic (2004) 13 also shown that Olopatadine HCl ophthalmic solution had an excellent tolerability profile; symptoms of ocular discomfort was reported in fewer than 5% in a clinical study. In our study none of 40 olopatadine treated subject complained such discomfort on eye.
Olopatadine produced significant clinical improvement of study subjects by 2 week in every evaluated parameter without producing any adverse events. Therefore treatment goal was achieved by olopatadine safely.
In a double-masked, multi-centered, randomized trial by Artal, Luna and Discepola (2000) 14 , 80 subjects were asked to make a choice based on ocular comfort between one drop of olopatadine hydrochloride 0.1% instillated in one eye and one drop of ketotifen fumarate 0.05% instillated in the contralateral eye. All subjects (100%) selected olopatadine as the more comfortable formulation. Our study design was different from this study but the result of our study showed that olopatadine is the more comfortable formulation. 100% of olopatadine treated group did not experience any adverse event. The treatment regimens were well tolerated.
A study from Uludag University, Bursa, Turkey showed that allergic conjunctivitis improved with topical olopatadine treatment (Dogru 2002) 15 . Another study showed that olopatadine and ketorolac ophthalmic solutions were found to be effective in alleviating the clinical signs and symptoms of Allergic Conjunctivitis compared to placebo, whereas olopatadine reduced ocular itching significantly more than ketorolac (Yaylali. 2003) 11 ; Deschenes, Discepola and Abelson 1999 16 ) and cromolyn sodium (Katelaris 2002) 17 . A study that was done in Harvard Medical School, Boston showed that topical olopatadine therapy was significantly more efficacious than oral loratidine in reducing ocular itching related to allergic conjunctivitis (Abelson and Welch 2000) 18 . Result of our study also demonstrates that olopatadine exerted a better control on signs and symptoms of allergic conjunctivitis.
The use of olopatadine provides good status of eye with no apparent risk of adverse events. Ophthalmologist concerned with the treatment of allergic conjunctivitis may consider olopatadine for effective control of signs and symptoms of allergic conjunctivitis.
This study was conducted on a small number of patients and it was a single center trial. The findings would have been more significant if a placebo group could be used.
Further prospective interventional multi-centered placebo control trials are suggested for better assessment of the effective and safety therapeutic modalities that may improve the outcome of allergic conjunctivitis.
Significance of difference in efficacy scores of olopatadine estimated before (on 1st day) and 2 weeks after administration at p < 0.001 (Paired t-test).
Adverse events:
No adverse events e.g. stinging sensation, headache, sedation, dry eye, were observed during the study period.
DISCUSSION:
Allergic eye disease is a common problem in daily practice which affects more than 20% of the world's population and impairs their daily activities; the numbers of victims are increasing day by day along with the environmental pollution and ophthalmologists are practically facing it daily.
Allergic conjunctivitis hampers quality of life. The goal of treatment for seasonal allergic conjunctivitis is to effectively resolve clinical signs and symptoms, and improve quality of life. The pharmacotherapy of allergic conjunctivitis consists of several classes of drugs: antihistamines, mast cell stabilizers, dual-acting agents, NSAIDS and corticosteroids.
The aim of treatment of allergic conjunctivitis is to antagonize histamine activity and to maintain stabilization of mast cells. Therefore the dual-acting drug, olopatadine that combine histamine-receptor antagonism and mast cell stabilization are important to block histamine-related symptoms as well as prevention of mast-cell degranulation.
As a combination mast cell stabilizer / antihistamine, olopatadine is a relatively newer drug with better safety profile.
In our study olopatadine hydrochloride 0.1% solution was instillated as a dose of one drop in each eye 12 hourly and evaluated accordingly (as designed). Olopatadine appeared significantly effective compared to Day 0 (p<0. 001) in allergic conjunctivitis. This study showed that olopatadine significantly reduced signs and symptoms of allergic conjunctivitis from base line.
A doubled blind placebo control study by Abelson and Turner (2003) 12 showed mean scores of ocular itching and hyperaemia were lower at all assessment times with olopatadine than placebo. The difference was statistically significant (P < 0.05) for itching on days 7 and for both itching and hyperemia on days 14. Our study also revealed that olopatadine is significantly effective against itching and hyperaemia after 2 weeks (p < 0.001).
One hundred patients with previous history and current symptoms of seasonal or perennial allergic conjunctivitis were enrolled by Leonardi and Zafirakis (2004) 7 in a study of patient preference, a significantly greater percentage of patients (81%) selected olopatadine when asked which medication they preferred; which they found more
